Literature DB >> 12230502

Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis.

Masahiro Iwasaki1, Kinya Nagata, Shoichi Takano, Kazuo Takahashi, Norihisa Ishii, Zenro Ikezawa.   

Abstract

Prostaglandin D2 is known to be the major prostanoid produced by allergen-activated mast cells, but its role in the formation of allergic diseases is not well established because of complexity of its receptor system and lack of appropriate inhibitors. We have recently identified a new-type prostaglandin D2 receptor, named CRTH2. Studies with normal subjects have shown that CRTH2 appears to be selectively expressed by T helper 2 cells but not T helper 1 cells among circulating CD4+ lymphocytes. The exact correlation between CRTH2 and T helper 2 cells in various disease settings and the impact of CRTH2-mediated prostaglandin D2 activities on various T helper 2 responses in vivo still remain to be elucidated, however. In this study, we investigated the correlation between CRTH2 and T helper 2 cells among circulating CD4+ lymphocytes in normal adults and patients with atopic dermatitis, a T-helper-2-involving disease. The results showed that virtually all CRTH2+CD4+ lymphocytes had a pure T helper 2 phenotype and formed not all but a large proportion of circulating T helper 2 cells for both normal and atopic dermatitis subjects. In chemotaxis assays, peripheral blood CRTH2+CD4+ lymphocytes were significantly attracted by prostaglandin D2 as well as by a typical T-helper-2-attracting chemokine, thymus and activation regulated chemokine, whereas they showed little chemotactic migration toward typical T-helper-1-attracting chemokines, macrophage inflammatory protein 1beta and interferon-gamma-inducible protein 10. Furthermore, in atopic dermatitis patients, a preferential increase of CRTH2+ cells was noted within the disease-related cutaneous lymphocyte-associated antigen-positive, but not the cutaneous lymphocyte-associated antigen-negative, CD4+ lymphocyte compartment. Our results suggest the involvement of the prostaglandin D2/CRTH2 system in both normal and pathogenic T helper 2 responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230502     DOI: 10.1046/j.1523-1747.2002.01862.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

1.  Dual functions of prostaglandin D2 in murine contact hypersensitivity via DP and CRTH2.

Authors:  Yoshihiro Yamamoto; Shinobu Otani; Hiroyuki Hirai; Kinya Nagata; Kosuke Aritake; Yoshihiro Urade; Shuh Narumiya; Hiroo Yokozeki; Masataka Nakamura; Takahiro Satoh
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

2.  Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.

Authors:  Stefano Crosignani; Catherine Jorand-Lebrun; Patrick Page; Gordon Campbell; Véronique Colovray; Marc Missotten; Yves Humbert; Christophe Cleva; Jean-François Arrighi; Marilène Gaudet; Zoe Johnson; Pamela Ferro; André Chollet
Journal:  ACS Med Chem Lett       Date:  2011-06-09       Impact factor: 4.345

Review 3.  Molecular biology of atopic dermatitis.

Authors:  Zhanglei Mu; Yan Zhao; Xiaojing Liu; Christopher Chang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

4.  A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes.

Authors:  Shân L Vinall; Elizabeth R Townsend; Roy Pettipher
Journal:  Immunology       Date:  2007-04-16       Impact factor: 7.397

Review 5.  Prostaglandins and inflammation.

Authors:  Emanuela Ricciotti; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05       Impact factor: 8.311

Review 6.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

7.  A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation.

Authors:  Stefen A Boehme; Karin Franz-Bacon; Edward P Chen; Roman Sásik; L James Sprague; Tai Wei Ly; Gary Hardiman; Kevin B Bacon
Journal:  Int Immunol       Date:  2008-12-09       Impact factor: 4.823

8.  Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms.

Authors:  Stefen A Boehme; Edward P Chen; Karin Franz-Bacon; Roman Sásik; L James Sprague; Tai Wei Ly; Gary Hardiman; Kevin B Bacon
Journal:  Int Immunol       Date:  2008-12-09       Impact factor: 4.823

9.  CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation.

Authors:  Nicholas W Lukacs; Aaron A Berlin; Karin Franz-Bacon; Roman Sásik; L James Sprague; Tai Wei Ly; Gary Hardiman; Stefen A Boehme; Kevin B Bacon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-08-29       Impact factor: 5.464

Review 10.  Animal models of ocular allergy and their clinical correlations.

Authors:  Margarita Calonge; Karyn F Siemasko; Michael E Stern
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.